FDA Finalizes Guidance on Prescription Drug Use-Related Software
FDA's final PDURS guidance sets out when software functions become a prescription drug, while signaling how the agency will defend that position against First Amendment challenges.
On October 21, 2026, the U.S. Food and Drug Administration published final guidance titled "Regulatory Considerations for Prescription Drug Use-Related Software" (PDURS Guidance). According to the account circulated by Ropes & Gray, the agency finalized the document while defending its authority to regulate certain software functions, a posture suggesting it expects litigation to test its position under the First Amendment.
Why sophisticated counsel should care: the boundary between a regulated device or drug function and unregulated software practice is the central commercial question for digital health companies, software platforms, and pharma and biotech partners building companion or dosing applications. Guidance that both explains the framework and stakes out a constitutional defense has implications for product design, premarket regulatory strategy, and the willingness of venture-backed issuers to pursue software-centric models in the prescription space. It also offers a foreseeable focal point for industry challenge to the agency's asserted jurisdiction.
Next steps to watch: how the final text distinguishes functions that merely relay information, support dosing, or control drug delivery; the treatment of devices, digital therapeutics, and software as a device or accessory; any enforcement-discretion or transition language; and whether stakeholders sue or seek reconsideration. Counsel should re-review product roadmaps and regulatory claims against the final framework, which supersedes the draft.